Related Experiment Videos
New clinical color threshold test for eye disease
American Journal of Optometry and Physiological Optics
|January 1, 1987
Summary
A new clinical test reliably detects early vision loss in short-wavelength sensitive cones (B cones), crucial for diagnosing retinal disorders. This simple test aids in identifying blue light sensitivity defects in conditions like diabetes and glaucoma.
Area of Science:
- Ophthalmology
- Visual Neuroscience
- Clinical Optometry
Background:
- Selective loss of blue light sensitivity, detected by short-wavelength sensitive cones (B cones), is an early indicator of various retinal and visual pathway disorders.
- Current diagnostic methods often lack the reliability and simplicity needed for early detection of these specific cone defects.
Purpose of the Study:
- To develop and validate a new, simple, and reliable clinical test for assessing B cone function.
- To provide a tool for early detection of visual pathway disorders characterized by blue light sensitivity loss.
Main Methods:
- Development of a novel, brief, forced-choice clinical test for B cone function.
- The test is designed to be independent of patient criteria for seeing and minimally affected by refractive errors or fixation changes.
- Comparison of results from three different tests within 5 minutes allows for the isolation of B cone function, correcting for age-related media yellowing and R/G cone function.
Main Results:
- The new test is brief, reliable, and unaffected by common clinical variables like refractive error and fixation instability.
- The test successfully demonstrated B cone sensitivity losses correlated with diabetic retinopathy severity in 60 patients.
- Selective B cone loss was also identified in patients with glaucoma and ocular hypertension.
Conclusions:
- A new clinical test effectively measures B cone function, offering a reliable method for early detection of visual pathway disorders.
- This test provides a valuable tool for diagnosing conditions such as diabetic retinopathy, glaucoma, and ocular hypertension by identifying specific blue light sensitivity deficits.